Klimek, Ludger
Casper, Ingrid
Bergmann, Karl-Christian
Biedermann, Tilo
Bousquet, Jean
Hellings, Peter
Jung, Kirsten
Merk, Hans
Olze, Heidi
Mösges, Ralph
Schlenter, Wolfgang
Gröger, Moritz
Ring, Johannes
Chaker, Adam
Pfaar, Oliver
Wehrmann, Wolfgang
Zuberbier, Torsten
Becker, Sven
Funding for this research was provided by:
Universitätsklinikum Tübingen
Article History
Received: 16 July 2019
Accepted: 31 March 2020
First Online: 20 July 2020
Conflict of interest
: S. Becker received grants, fees and non-financial support from Ambu, ALK-Abelló, Allergopharma, Bencard Allergie GmbH, Bristol-Myers Squibb, HAL Allergie and Sanofi Genzyme, outside of the present work. T. Biedermann received grants and/or fees from Alk-Abelló, Astellas, Bencard, Biogen, Janssen, Leo, Meda, MSD, Novartis, Phadia and Thermo Fisher, outside of this work. Outside of this work, J. Bousquet received fees from and worked as an adviser (advisory board member, lectures) for Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach and Kyomed. L Klimek received grants and/or fees from Allergopharma, Meda/Mylan, HAL Allergy, ALK-Abelló, Leti Pharma, Allergy Therapeutics, Stallergenes, Quintiles, Sanofi, AstraZeneca, GSK, ASIT Biotech and Lofarma, outside of this work. L. Klimek is also President of the AeDA and a member of the following companies: DGHNO, DGAKI, GPA and EAACI. R. Mösges received fees and/or grants and/or non-financial support from ALK-Abelló, ASIT Biotech, Allergopharma, Allergy Therapeutics, Bencard, Leti Pharma, Lofarma, Roxall, Stallergenes, Optima, Friulchem, Hexal, Servier, Klosterfrau, Atmos, Bayer, Bionorica, FAES, GSK, MSD, Johnson & Johnson, Meda, Novartis, Otonomy, Stada, UCB, Ferrero, BitopAG, Hulka, Nuvo and Ursapharm, outside of this work. H. Olze is a member of the Advisory Board at Meda Pharma. O. Pfaar received grants and/or fees from ALK-Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding/HAL Allergie, Bencard Allergie/Allergy Therapeutics, Lofarma, Biomay, Circassia, ASIT Biotech Tools, Laboratorios Leti/Leti Pharma, Meda Pharma/Mylan, Anergis, Mobile Chamber Experts (a GA2LEN partner), Indoor Biotechnologies, GSK, Astellas Pharma Global, Euforea, Roxall, Novartis and Sanofi Aventis, outside of this work. J. Ring received fees from Mylan, Allergics, Galderma, Sanofi-Genzyme, ThermoFisher and Leo Pharma, outside of the present work. T. Zuberbier received fees (for example for lectures, advice, expert opinions) from Bayer Health Care, FAES, Novartis, Henkel, Novartis, Henkel, AstraZeneca, Abbvie, ALK, Almirall, Astellas, Bayer Health Care, Bencard, Berlin Chemie, FAES, HAL, Leti, Meda, Menarini, Merck MSD, Novartis, Pfizer, Sanofi, Stallergenes, Takeda, Teva, UCB, Henkel, Kryolan and L’Oréal, outside of this work. I. Casper, K.-C. Bergmann, P. Hellings, K. Jung, H. Merk, W. Schlenter, M. Gröger, A. Chaker and W. Wehrmann declare that there are no conflicts of interest.